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ABSTRACT
Silicon and germanium containing heteroammatic sulfides have been prepared using
phase transfer catalytic (PTC) system thiol / Si or Ge containing alkyl halide / solid KOH / 18-
crown-6 / toluene. The target sulfides were isolated in yields up to 92 %. It has been found that 2-
{[d methy (l-triethyIgermylethyl)-silylmethyl]thio}-1 -methylimidazole and 2-{[dimethyI(l-
triphenylsilylethyl)silyl-methyl]thio}benzothiazole are the most active cholesterol level lowering and
vasodilating agents.
INTRODUCTION
Coronary heart desease (CHD) remains the leading cause of death in the industrialized
countries. The primary cause of CHD is athemsclemsis, a disease characterized by the deposition
of lipids in the artedal vessel wall, resulting in a narrowing of the vessel passages and ultimately
hardening the vascular system.
Atherosclerosis as manifested in its major clinical complication, ischaemic heart disease, is
thought to begin with local injury to the arterial endothelium followed by proliferation of artedal
smooth muscle cells from the medial layer to the intJmal layer along with deposition of lipid and
accumulation of foam cells in the lesion. As the athemsclerotic plaque develops, it progressively
occludes more and more blood vessel and can eventually lead to ischaemia or infarction.
Therefore, it is desirable to provide a method of inhibiting the progression of atherosclemsis in
patients.
Elevated cholesterol levels are also associated with a number of disease states. Therefore it
is desirable to provide a method for reducing plasma cholesterol in patients with, or at risk of
developing restenosis, angina, cerebral arteriosclerosis, and xanthoma.
Hetemcyclic sulfides exhibit a wide spectrum of activity on heart and blood cimulatory
system. For example, pyridine sulfides display cholesterol acyltransferase inhibitor [1], blood sugar
reduction [2], vasodilating [3-7], vasopressing [8], antihypertensive [4, 5, 7, 9, 10], hypotensive [6],
hypoglycemic [11-13], anticholesteremic [14], euglicemic and hypolipidemic [15], cardiotonic [16],
cardiovascular and cardioprotective [17] activities. Quinoline sulfides exhibit vasodilating [18-24],
antihypertensive [18, 19], hypotensive [23, 30], euglicemic and hypolipidemic [15], antithrombotic
[31, 32] and cardiotonic [32] activities. Thiazole and benzothiazole sulfides display vasodilating [33-
35], and hypotensive [35] activities and may be used as hypolipemics and in treatment of
arteriosclerosis [36]. Imidazole sulfides increase high density lipoprotein cholesterol over lipid
fractions [37] and were used in the treatment of athemsclerosis [38]. Hypoglycemic activity of N-{4-
[2-(pyrazole-l-carbonylamino)ethyl]benzenesulfonyl}urea [39] and vasodilating activity of 6-
quinazolinesulfonyl derivatives [40] are evaluated too.
The silicon and germanium containing heteroammatic sulfides as cholesterol level lowering
and vasodilating agents have not been studied. In this view the silyl and germyl S-substituted
derivatives of N- and S-heterocyclic thiols are of interest as substances with the possible above
described activity.
The preparation of the compounds possessing serum cholesterol level lowering property [41]
is the aim of our work.
The known methods for the preparation of hetan/I sulfides are based on the reaction of
hetaryl thiols with alkyl or aryl halides in the K2CO3 / Me2CO [42], NaOMe / DMF [43] or Nail /
Me2SO, [44] systems. Recently we described two simple phase transfer catalytic (PTC) methods
for the preparation of hetaryl sulfides in the hetaryl thiol / alkyl halide / solid K2CO3 / 18-crown-6 /
toluene [45] or hetaryl S-acetate / aikyl halide / solid KOH / 18-crown-6 / benzene systems [46].
We have used the first [45] of these methods for the preparation of Si and Ge derivatives of
N-methylimidazole, pyridine, quinoline, benzothiazole, and purine sulfides to test their serum
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MATERIAL8 AND METHODS
CHEMISTRY H NMR spectra were recorded on a Varian 200 Mercury instrument using CDCI as
solvent and hexamethyldisiloxane (HMDSO) as internal standard. Mass spectra were registered on
a GC-MS HP 6890 (70 eV). GC analysis was performed on a Chrom-5 instrument equipped with
flame-ionization detector using glass column packed with 5 % OV-101 / Chromosorb W-HP (80-
100 mesh) (1.2 m x 3 mm). Bromomethyltdmethylsilane and 3-iodopropyltrimethylsilane were
obtained by Gdgnard reaction [47, 48].
HYDROSILYLATION AND HYDROGERMYLATION REACTIONS OF CHLOROMETHYLVINYL
D/METHYLS/LANE. GENERAL PROCEDURE.
A mixture of 0.01 mol ,of tdalkyl(aryl)hydmsilane (germane), 0.01 mol of
chloromethylvinyldimethylsilane and 10 M% of Speier’s catalyst were stirred for 4 h in a Wheaten
vial at room temperature. Processes were controlled by GLC. Products la-d were purified using
vacuum distillation or recrystallization from pentane.
HALOGEN EXCHANGE REACTION. GENERAL PROCEDURE.
A mixture of I-(trialkyl(aryl)silyl(germyl)ethyl)silylmethyl chloride la-d (0.01 mol) and 3.5
fold excess of dnj sodium iodide was refluxed in acetone for 12 hours. Alkyliodides 2a-d were
pudfied using vacuum distillation or recrystallization from pentane/methylene chloride.
SYNTHESIS OF SILYL AND GERMYL DERIVATIVES OF HETARYL THIOLS. GENERAL
PROCEDURE.
Finely powdered dry K2COz was added to a solution of 10 mmol of thiol (3- 9), 10 mmol of
corresponding silyl or gerrnyl substituted alkyl halogenide and 18-crown-6 (lmmol, 264 mg) in 25
ml of toluene. The mixture was refluxed with stirring to achieve the disappearance of the
substrates, filtered over the thin silica gel layer and concentrated under reduced pressure. The
residue was purified by column chromatography using the mixture benzene-ethyl acetate as eluent.
PHARMACOLOGY
CHOLESTEROL LEVEL LOWERING ACTIVITYASSAY
Five months old male ICR mice were housed in an air-conditioned room (23 C and 60%
humidity) under an artificial 12-hr light-dark cycle (7:00 am- 7:00 pm). Animals were maintained on
a basal diet or a high-cholesterol diet supplemented with linoleic acid. The basal diet contained
20% casein, 63.2% sucrose, 10% coconut oil (linoleic acid content: below 1%), 2 % agar, 0.8%
vitamin mixture, and 4% salt mixture. The high cholesterol diet consisted of the basal diet plus
1.5% cholesterol and 10% linoleic acid, but the corresponding 2% of sucrose were omitted from the
basal diet. We divided 50 mice into 2 groups and gave different diets as follows: for 10 mice the
basal diet (control group), and for 40 the high cholesterol diet (HC group). Each animal received
5 g of the respective diet daily for 12 weeks. Water was freely available.
9 Weeks after start of the experiment the total and HDH cholesterol were determined in the
serum of intact control and high-cholesterol diet animals (3 from each group). High-cholesterol diet
group was divided into Cholesterol control group (7 mice) and 5 groups (6 mice each) treated with
the studied compounds (10 rng/kg i.p. once a day for 3 weeks).
At the end of the experiment (12 weeks), the mice after overnight fasting were killed by
withdrawing blood from the abdominal aorta under ether anaestesia. Serum was separated by
centrifugation (1500 g for min), and high-density lipoprotein (HDL) fraction was immediately
separated from a portion of the serum by the heparin-manganese precipitation procedure.
Total and HDL cholesterol in the serum and aorta were determined flumenzymatically.
The results obtained were expressed as the mean + SEM of data from 5- 7 mice per group.
VASODILATINGACTIVITYASSAY
The modified classical method for the experiments on the isolated perfused rabbit ear blood
vessels was used. Rabbits of both sexes (2.6-3.3 kg) were killed by i.v. injection of pentobarbital
sodium (80 rng/kg). The central ear artery was dissected free at the base of the ear and cannulated
with polyethylene tubing and perfused at a constant flow (2ml/min) from 4-channel peristaltic pump
Gemini (Italy).
The content of the perfusion fluid (mmol) was as follows: NaCI 136.9; KCI 2.68; CaCI2 1.8;
MgCI2 1.05; NaHCO3 11.9; NaH2PO4 0.42; glucose 5.6 (pH 7.35 at 22C). Intraluminal inflow
perfusion pressure was measured with a Statham P23J transducer and recorded on the
physiograph DMP-4B (Narco Bio-Systems, USA). As flow remained constant, the changes in
perfusion pressure reflected changes in blood resistance, i.e. the degree of vasoconstriction or
relaxation. Vasoconstriction was caused by intraluminal infusion of noradrenaline (10 /mol). The
investigated compounds were dissolved in the perfusion fluid. The relaxant responses to the
investigated compounds used in the different concentrations (10 and 50 /mol) were tested.
Responses are expressed as per cent relaxation (% changes in the perfusion pressure) without
and with the investigated compounds.
ACUTE TOXICITYASSAY
The acute toxicity was evaluated in male ICR-JCL mice (19-23 g). The compounds were
dissolved-suspended in 0.6% solution of Twin 80 and injected i.p. To reduce the number of the
used animals and the amount of compounds the maximal dose (400-600 mg/kg, i.p.) was used. If
possible LDs0 was calculated when 50% of the animals died.
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RESULTS AND DISCUSSION
CHEMISTRY
Hydrosilylation and hydrogermylation of the chloromethylvinyldimethyisilane with
diethylmethylsilane, triethylsilane, triphenylsilane, and triethylgermane have been used to obtain
silyl(germyl)containing alkylchlorides la- d. Trialkyl(aryl)silane or germane was added to
vinylsilane in the presence Speier’s catalyst (0.1 M solution H2PtCI.6H20 in absolute isopropyl
alcohol). The reactions were exothermic and gave 1,3-disilyl(germyl)substituted ethanes in good
yields (up to 98 %) (Table 1).
It was necessary to transform the silyl(germyl)containing alkylchlorides la d into iodides
due to the low reactivity of alkylchlorides under phase transfer catalysis conditions. The chlorine
atom exchange for iodine was performed with Nal in acetone by usual procedure giving the
corresponding alkyliodides 2a- d (in yields up to 74 %) (Table 1).
\ RsMH \ / NaI \ .//
CI\../Si.
,- C1......//Si./- HzPtCI6 MRs Me2CO
la-d
Table 1. Silyl and germyi containing alkylhalogenides la d, 2a d.
N" RM b.p o. (m.p.), Yield, % MS-GC (m/z)
C/ram
la F:t2MeSi 106-108/15 87 236 (M, 12), 101 (100)
lb Et3Si 114-117/15 70 250 (M 15), 115 (100)
lc Ph3Si (55-56) 98
ld Et3Ge 122-124/15 77 296 (M*, 26)’161 (100)
2a Et2ieSi 128-131115 74 328 _(M, 5), 101 (100)
2b Et3Si 136-138/15 58 327 (M -15, 21), 115
(100)
2c Ph3Si (48-49) 54
2d Et3Ge 132-134/10 66 375 (M*-15, 22), 115
(100)
2a d
A simple method for the preparation of silyl and germyl derivatives of the N- and S-
heterocyclic thiols was developed. The phase transfer catalytical system solid K2CO/18-crown-
6/toluene was used. Application of the stronger base (KOH) led to the destruction of alkylating
agents. Despite to the mild reaction conditions triphenyisilyl derivative 2c partly decomposed.
Therefore the yield of 2-{[dimethyl(l-triphenylsilylethyl)silylmethyl]thio}benzothiazole Sd was 13%.
The aimed substances were obtained with good chemical yields (up to 92%) in a short time
under mild conditions (Table 2).
RI / K2CO3 / 18-crown-6
HetSH toluene / reflux
> HetSR
3- 9 3 (a-e)- 9 (a-e)
The purity of the synthesized compounds was detected with HPLC (<1.5% of impurities). All
substances were mobile oils therefore the elemental analysis was performed only for 8a and 9a.
The structures and spectral characteristics of synthesized substances are shown in Tables 3
and 4.
Table 2. Synthesis of element containing derivatives of hetaryl thiols (HetSH RI K2CO 18-
crown-6 = 1 1 4 0.1 ) *HetSH RI = 1 2; S- and N-disubstituted derivatives were obtained.
’Thiol Het R Reaction Pro’- Isolate’i"
time, h duct yield, %
3 2-(1 -methylimidazolyl) (CH2)3SiMe3 8 3a 61
:3 2-(1-methylimidazolyl) CH2SiMe2(CH2)2SiEt2Me 5 3b 84
3 2-(1 -methylimidazolyl) CH2SiMe2(CH2)2GeEt3 6 3e 93
4 2-pyddyl (CH2)3SiMe3 8 4a 66
5 4-pyddyl (CH2)3SiMe3 7 5a 62
6 2-quinolyl (CH2)3SiMe3 7 Sa 53
7 8-quinolyl (CH2)3SiMe3 7 7a 33
8 2-benzothiazolyl (CH2)3SiMe 10 8a 65
8 2-benzothiazolyl CH2SiMe2(CH2)2SiEt2Me 6 8b 83
8 2-benzothiazolyl CH2SiMe2(CH2)2SiEt3 5 8c 62
8 2-benzothiazolyl CH2SiMe2(CH2)2SiPhz 5 8d 13
8 2-benzothiazolyl CH2SiMe2(CH)GeEt3 6 8e 73
9 1- and 6-puryl* (CH2)3SiM .9 9a 35. 87Edmunds Lukevics et al. Synthesis ofSilion andGermanium ContainingHeteroaromatic
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Table 3. H and 3C NMR data of hetemaromatic sulfides 3a 9a
Sulfide Structure
of HetSR
3a
3b
3e
-N
SCH2i(CH2)2iM
Me Me Et
H NMR,
(ppm, CDClz I HMDSO)
"0.03 is, 9H, Si(CH3)3), 0191
’C NMR, (ppm, CDCI i
HMDSO)
Het
121186 (C5),
2H, CH2Si), 1.64 (m, 2H,
CH2CH_2CH2Si), 3.10 (t, 2H, J=
7.0 Hz, SCH2), 3.60 (s, 3H,
NCH), 7.20 (m, 2H, imidazole
protons).
-0.10 (s, 3H, Et2sicH__3); 0.i0 121,79 (C-S),
129.13 (C-4),
142.02 (C-2),
33.11 (NCH3)
-1.81,
16.07,
24.53,
37,81
-4.13,
Sa
SCH2S,i(CHz)2CmEt3
Me Me
’
S(CH2)aSiMe3
(s, 6H, Si(CH3)2); 0.46 (m, 8H,
CH2Si); 0.90 (m, 6H,
SiCH2CH3); 2.42 (s, 2H,
SCH2);, 3.57 (s, 3H, NCH3);
6.88 (d, 1H, J=1.2 Hz, H-5);
7.02.(d., 1 H; J=..1...2 Hz,. H-4)
0.10 (s, 6H, Si(CHa)2); 0.72 (m,
10H, CH2Si and CH2Ge);; 0.99
(t, 9H, J= 7.4 Hz, GeCH2CH3);
2.43 (s, 2H, SCH2); 3.57 (s,
3H, NCH3); 6.87 (d, 1H, J=1.2
Hz, H-5); 7.02 (d, 1H, J= 1.2
128.79 (C-4),
144.69 (C-2),
32.83 (NCH3)
121.76 (C-5),
4.46,
4.60,
17.07
128.76 (C-4),
144.65 (C-2),
32.79 (NCH3)
3.19,
3.37,
8.61,
8.93,
17.04
S(CH2)3SiMe3
S(CH2)aSiMe3
S(CH2)3SiMe3
Hz, H-4)
0’1’3 (s’, ’gH,’ Si(CH3)3), 0.72 (m,
2H, CH2Si), 1.80 (m, 2H,
CH2CH_2CH2Si), 3.27 (t, 2H, J=
7.6 Hz, SCH2), 7.00 (m, 1H, 5-
H), 7.25 (m, 1H, 3-H), 7.91(m,
1H,..4,1-1), 8.49. (m., 1 H, 6-.H).
-0.01 (s, 9H, Si(CH3)3); 0.66
(m, 2H, SiCH2); 1.70 (m, 2H,
CH2CH__2CH2); 2.97 (t, 2H,
J=8.0 Hz, $CH2); 7.09 (dd, 2H,
J= 4.0 Hz, J2= 1.4 Hz, H-3,4),
8.38 (dd, 2H, J= 4.0 Hz, J2=
1.4 Hz, H-2,6)
0.01 (s, 9H, Si(CH3)3); 0.76 (m,
2H, SiCH2); 1.80 (m, 2H,
CH2CH_.2CH2); 3.35 (m, 2H,
  8.89 (c-s),
121.19 (C-3)
135.59 (C-4),
149.21 (C-6),
161.32 (C-2)
"120.57" (C-3, C-
5), 149.18 (C-2,
C-6), 149.46 (C-
4)
 2 .o4 (c,3),
125.03 (C-6),
125.87 (C-4a),
-1.70,
15.40,
22.60,
33.25
16.47,
23.40,
34.14
SCH2); 7.20- 8.00 (m, 6H, 127.55 (C-5),
protons of the cycle) 128.01 (C-7),
129.48 (C-S),
135.11 (C-4),
148.36 (C-8a),
159.60..(C-2)
0.13 (s,"gHi ’si(cH3)3), 0.93 (m, i2i’149 (c-3),
33.20
-1.80,
2H, CH2Si), 2.47 (m, 2H,
CH2C_CH2Si), 3.73 (t, 2H, J=
7.0 Hz, SCH2), 7.60, 8.26 and
9.06 (all m, 6H, quinoline cycle
protons)
123.54 (C-5),
123.76 (C-7),
126.48 (C-6),
128.20 (C-4a),
136.27 (C-4),
138.98 (C-8),
145.51 (C-8a)
149.09 (C,2)
16.66,
23.12,
34.54
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Me Et % $CH2i(CH2)2iMe
S Me Et
SCH2tSi(CH2)2SiEt3 S Me
0.13(s, 9H, si(CH3)3), 0.8i (m,
2H, CH2$i), 1.84 (m, 2H,
CH2C..2CH2Si), 3.46 (t, 2H, J=
7.4 Hz, 8CH2), 7.46 and 7.92
(m, 4H, benzothiazole cycle
protons)
-0.09’ (s, 3H, Et2si’C.H_3); 0.i’6
(s, 6H, Si(CH3) 2); 0.51 (m, 8H,
CH2Si); 0.90 (t, 6H, J=3.3Hz,
SiCH2CH3); 2.61 (s, 2H,
SCH2); 7.31 (m, 2H, H-5,6);
7.80 (m, 2H, H-4,7)
0.18 (s, 6HI Si(CH3)2);0152 (m,
10H, CH2Si); 0.91 (m, 9H,
SiCH2CH3); 2.63 (s, 2H, SCH2-
); 7.31 (m, 2H, H-5,6); 7.79 (m,
2H, H-4,7)
120,87 (C-7)I
121.43 (C-4),
124.04 (C-6),
125.95 (C-5),
135.15 (C-7a),
153.38 (C-3a),
SCH2ISi(CH2)2SiPh3
Me
167.3.8 (C-2)
120.87 (C-7),
121.25 (C-4),
123.84 (C-6),
125.93 (C-5),
135.24 (C-7a),
153.58 (C-3a),
SCHSIi(CHzGoEt
2)3SiMe3
(CH2)3SiMe3
123.84
125.94
135.24
153.57
(c-4),
(c-),
(c-s),
(C-7a),
(C-3a),
170.86 (C-2)
0.17 ’(s, 6H, Si(CH3)2);0.76’ 120.91 (C-7),
121.29 (C-4),
123.90 (C-6),
125.98 (C-5),
135.26 (C-7a),
153.53 (C-3a),
.1.70.56 (C-.2)
0.16’(S, 6’,’ Si(CH3)2)"i’0.68 (m, 120.88 (C-7),
and 1.34 (both m, 4H, SiCH2);
2.63 (s, 2H, SCH); 7.35 (m,
2H, H-5,6); 7.50 (m, 15H, Ph);
7.80 (m, 2H, H-4,7)
10H, CH2Si and CH2Ge); 0.99
(m, 9H, GeCH2CH3); 2.67 (s,
2H, SCH2); 7.33 (m, 2H, H-
5,6); 7.80 (m, 2H, H-4,7)
and 1’.84 (both s, 9H,
’1,74,
16.37,
24.25,
37.04
-3.93,
4.46,
4.65,
6.99,
7.38,
17.0.84 (C,2) 17.47
120.87 -3.95,
121.25 2.79,
2.85,
3.29,
6.99,
7.44,
17.46
-3.86,
5.27,
7.50,
17.32
121.26 (C-4),
123.85 (C-6),
125.95 (C-5),
135.24 (C-7a),
153.58 (C-3a),
!7088 (C-2)
131.41 (C-
5),142.48 (C-8),
148.32 (C-4),
151.77 (C-2),
16.40 (C-6)
Si(CH3)3), 0.34 (m, 2H,
S(CH2)2CH_2Si), 0.57 (m, 2H,
N(CH2)CH__2Si), 1.67 (m, 4H,
CH2C_H_2CH2Si), 3.26 (m, 2H
SCH2), 4.08 (m, 2H, NCH2),
7.80 (s, 1H, 8-H), 8.57 (s, 1H,
.2-H)
-3.91,
3.21,3.43
,8.72,8.9
9, 17.48
-1.76,
13.63,
16.33,
24.40,
24.83,
32.05,
46.98
PHARMACOLOGY
CHOLESTEROL LEVEL LOWERING ACTIVITY
The compounds 38, b, e; 48; 58; 6a; 7a; 8a, b, c, d, e and 9a were tested as the cholesterol
level-lowering agents.
The Table 5 data show the serum lipid level at the end of the experiment. The high
cholesterol in nutrition Cholesterol group showed the marked increase in the total and LDL
cholesterol in comparison to the intact control group. Investigated compounds showed more or less
significant protection against increasing in serum total and LDL cholesterol level and the raising of
the atherosclerotic coefficient.
It has been found, that 2-{[dimethyl(-triethylgermylethyl)silylmethyl]thio}-l-methylimidazole
(3e), 2-{[dimethylC6-triphenylsilylethyi)silylmethyl]thio}benzothiazole (8d), 2-[(y-
trimethylsilylpropyl)thio]quinoline ($a) and 2-{[dimethyl(l-methyldiethylsilylethyl)silyl-
methyl]thio}benzothiazole (8b) exhibit the highest level of activity.
The comparison of compounds containing the different heterocycles showed that 2-(7-
trimethylsilylpropyl)thioquinoline 6a was more active than thiopyridine analogue 4a. The 2-[(1-N-
methyl)thio]imidazole derivative 3b was more active than derivative 8b. Holesterol level lowering
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effect induced by 2-{[dimethyl(l-tdethylgermylethyl)silylmethyl]thio}-l-methylimidazole 3e was
higher than in the case of 2-{[dimethyl(-tdethyl-germylethyl)silylmethyl]thio}benzothiazole Be.
The cholesterol level lowering activity depends also on the substituent position in the ring:
the 2-position in the pyddine and quinoline is more preferable. Thus 2-[(y-tdmethylsilylpropyl)thio]
derivatives of pyridine 4a and quinoline 6a are more active than the similar derivatives of 4-pyddine
5a and 8-quinoline 7a.
Table 4. Mass spectra of hetemaromatic sulfides
Sulfide m/z relative intensi.ty%)
3a 228 (M*,’ 5), 213 (M+’Me, 1’0), 1’81 (17), 171 (39), 114 (100), 73 (49)i 72 (15),’59 (1’1), 45
918),..4.3 .(10), 41 .(13)
-3b 313 (M’-I, <1), 187 (8), 186 (14), 18, (100), 73 (13), 59 (9).,. 45"(13)
3e !359 (M/’ Me, <1), 187 (9), 18= (14), 185 (100’ /
’4a 225 (M/, 4), 210(M/-ie, 15), 182 (12), 178 (16), 168 (37), 13’8’ (i7)’, 125 (19),’ 124 (12),’
6a
8b
112 (16), 1 1 (100), 78 (22), 73 (59), 59 (11), 45 (22), 43 (14)
’225 (M" 5 211 (18), 210 (M/-Me, 97), 183 (10), 169 (10), 168 (58), 78’(10), 73 (SiMe3,
100), 59 (15), 51 (16), 45 (23), 43 (13), 39 (12)
275 (M 3), 200 (10), 228 (10), 218 (20), 188 (16), 175 (21)’, ’6i (1’00), 128 (40), 101
(13), 73 3;), 45 (14)
27’ (M+-,), 260 (M+-Me,’ 10),242 (23), 218 (23),"188 (48), 175 (28), 174 (100), 16i-
14; ’1 :)), 130 . 1.), 129 .(24), 73 (59), 45 (23), 43 (10)
81 (M*," ), 266 (M -Me, 8), 234 (18), 224 (25), 68 (12), 167(i00), 73 (69, 59 (10), 45
(24), 43 (10)
352 (M."- I Is, 2), 239 (!8), 238 (100), 73 (20), 59 (13), 45 (17)
366(M+..,’21; 240 ((15), 239 (18), 238 (100), 87 (10), 59 (15) ’..
Table 5. Effect of hetaryl sulfides on the lipoprotein level and the atherogenicity coefficient
(K) on mice with the high cholesterol in nutrition
Group Cholesterol, mgldl
K
Total HDL LDL
Cholesterol 120.8 +/- 21.3"* 72.2 +/- 13.6 486’+/- 15.7"* 0.695 +/-
0.266"**
3a 105.5 +/- 13.9" ’72.6 +/-’ 8.5 32.9 +/- 21.4" 0.453 +/- 0.327**
3b 95.0 = 16.0 72.2 = 8.2 22.8 +/- 12.6" 0.316 = 0.168"-
3e 93.3 = 13.8 82.3 = 14.0 10.9 = 4,6" 0.t37 = 0.063-=
4a 106.4 = 22.0* 77.4 +/- 14.2 29’.0’+/- 16.4" 0.375 +/- 0.228*-
5a 103.6 = 14,6" 69.9 +/- 5.6 33.7 +/- 14.2’ 0.486 = 0,203**
6a 96.6 = 20.1 75.7 +/- 183’ 20.) +/- 8.6 0.291 +/- 0.131"
7a 86.7 =’15.2 65.36 +/- 172 21.3 +/- 9.8 0.327 +/- O.170"
8a 84.2 15.8 65.6 +/- 7.2
8b 92.3 +/- 19.3 71.4 +/- 8.8
8c 87.3 = 11.9 65.4 = 1413
8d 82.7 +/- 208 71.4 +/- 16.2
8e 96,8 +/- 16.0 67.8 +/- 5.0
9a 109.5 : 26.30"" 70.3 +/- 8.5
Intact Control 8i.8 = 5.9 77.7 +/- 10.4
18.7 = 13.6 0.285 = 0.210
20.8 = "1 0" 0.283 = 0.124"
21.8 = 7.2* 0.357 = o.162"--
11.3 +/- i017 0.157 +/- 0.137-
29.0 ’+/- 13.2* 0.424 +/- o.191"
39.3 -
28.3* 0.559 +/- 0.459**
4.1 +/- 6.0 0.053 +/- 0,092
P>0.05 vs Intact Control
P>0.01 vs Intact Control
P>0.001 vs Intact Control
The study of 2-thiobenzothiazole derivatives showed that their activity increased as follows:
2-{[dimethyl(l-triethylgermylethyl)silylmethyl]thio}benzothiazole lie << 2-{[dimethyl-(l-
triethylsilylethyl)silylmethyl]thio}benzothiazole 8c < 2-[(3-trimethylsilylpropyl)thio]benzo-thiazole 8a
2-{[dimethyl(l-methyldiethylsilylethyl)silylmethyl]thio}benzothiazole 8b < 2-{[dimethyl(l-
triphenylsilylethyl)silylmethyl]thio}benzothiazole 8d.
VASODILATING ACTIVITY
Vasodilating activity of ten substances 3a, b, e; 6a; 8a, b, c, d, e and 9a has been studied
(Table 6).
We have found that imidazole derivatives 3a, b, e exhibit high vasodilating activity in
experiments in vivo. The most active was 2-{[dimethyl(l-triethylgermylethyl)silylmethyl]thio}-l-
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methylimidazole (3e). The exchange of imldazole ring to benzothlazole, quinoline or purlne
decreases the vasodilating activity. Unexpectedly, the replacement of triethylsilyl group in the
compound 8c by triphenyl group (8d) changes the action type from strong vasodilation to medium
vasoconstriction.
Table 6. Vasodilating activity of hetaryl sulfides on rabbit’s ear artery.
COmpound concenrati’on, ’FM Reiaxation (’-"contction),%
3a i0 i3.
50 36
3b 10’ ]2.
50 26
3e 10 22
50 38
6a 10 6
50 17
8a i0 3
50 -19
8b 10 10
50 20
50
8 i0 -12
5O -20
8e 10 3
5o 10
9a 10 1 i
50 22
c0ntmliSolvnt
P < 0.05 vs control
Compounds 2-[(3-trimethylsilylpropyl)thio]benzothiazole (8a) and 2-{[dimethyl(l-
triphenylsilylethyl)silyimethyl]thio}benzothiazole (Sd) have shown the highest contraction effect.
ACUTE TOXICITY
The acute toxicity ofthe substances 3a, b, e; Sa and 8a, b, c, d, e, that were investigated
as the cholesterol level Iowedng and vasodilator agents, was also determined (’l’able 7).
Table 7. Acute toxicity of the heteroaromatic sulfides
ComPound LDS0(mgikg ip)"
3a 210 -0---20-40)
3b 200 (152,9-282,98)
3e 435 (310,7-609,0)
6a > 600
8a 240 (145,5-396,0)
8b > 600
8c > 600
8d > 600
8e > 600
The studied compounds have a medium toxicity. The most toxic was silyl substituted
imidazole sulfide 3b (200 mg/kg). The replacement of silicon atom by germanium one (3e) leads to
the decrease of acute toxicity (435 mg/kg). In general, silyl and germyl substituted benzothiazoles
(Sb e) are less toxic than the corresponding imidazole analogues (3b, lh).
CONCLUSIONS
The PTC method of the synthesis of hetemcyclic silyl- and germylalkylsulfides was elaborated.
Thirteen compounds were synthesized and isolated in the yield up to 92%. !Edmunds Lukevics et al. Synthesis ofSilion andGermanium Containing Heteroaromatic
Sulfides as Cholesterol Level Lowering and VascodilatingAgents
They were studied as serum cholesterol level lowering agents. It has been found that silicon
and germanium containing heteroaromatic sulfides possess the cholesterol level lowering activity.
The 1-methylimidazole, benzothiazole and 2-quinoline derivatives 3e, 6a, 8a, b, e exhibit the
highest level of activity. The substances containing dimethyl(l-triethylgermylethyl)silylmethyl-(3e)
and dimethyl(l-triphenylsilylethyl)silylmethyl-(8d) substituents were the most active.
Ten of the elaborated compounds were tested on the vasodilating activity. It was shown
that 1-methylimidazole derivatives 3a, 3e possess the vasodilating activity.
The compounds containing benzothiazole have the different influence. Compound with
dimethyl(l-triethylsilylethyl)silylmethyl-substituent (8c) has the relaxation effect. On contrary the 3-
trimethylsilylpropyl-(8a) and dimethyl(l-triphenylsilylethyl)silylmethyl (8d) benzothiazole
derivatives possess the contraction effect.
The toxicity of the studied substances was low. It was shown that germanium derivative 3e
was less toxic than its silicon analogue 3b. The introduction of the second silicon or germanium
atom also decreases acute toxicity of the compound (Sa and 8b, c, d, e).
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